Dr. Gilly is the founding chairman and CEO of Fovea Pharmaceuticals and senior vice president of Sanofi’s ophthalmology division, which was formed after the acquisition of Fovea.
“Dr. Gilly is a seasoned entrepreneur in the biotechnology industry having spent over 20 years building and investing in leading life science companies. His track record and expertise in the ophthalmology space is an invaluable addition to Kala as we advance our pipeline of transformative ophthalmic products into the clinic,” said Dr. Guillaume Pfefer, Kala’s president and CEO, in the release.
Related Articles on Ophthalmology:
Prevent Blindness America Elects National Board of Directors Members
Bascom Palmer to Establish Orbital Vision Research Center
Eye Centers of Northwest Ohio Opens New Office in Fostoria
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
